

# Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028

<https://marketpublishers.com/r/GA0CC3DFF48AEN.html>

Date: December 2023

Pages: 1500

Price: US\$ 6,000.00 (Single User License)

ID: GA0CC3DFF48AEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028  
Report Findings & Highlights:

Global Cancer Antibody Combinations Market Opportunity: > USD 40 Billion By 2028

Insight On Approved Cancer Antibody Combinations In Market: > 65 Antibodies Combinations

Insight On Cancer Antibody Combinations In Clinical Trials: > 450 Antibodies Combinations

Patent, Pricing, & Dosage Insight On Approved Combinations

Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication & Phase

Global Antibody Combinations Market Development by Region & Indications

Combinations Included In Report:

Approved Antibody - Antibody Combinations

## Approved Antibody - Small Molecule Inhibitors Combinations

Approved Antibody - Immunomodulatory Agents Combinations

Approved Antibody - Chemotherapy Combinations

Approved Antibody - Mixed Combinations

Ongoing Clinical Trials Combination With Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Radiotherapy

In recent years, the landscape of cancer therapeutics has witnessed a paradigm shift with the emergence of antibody combination therapies, a dynamic approach that intertwines the precision of antibodies to target specific molecules with the synergistic benefits of different types of antibodies. By merging different types of monoclonal antibodies with other therapeutic agents, numerous pathways that are involved in the pathogenesis of cancer may be targeted simultaneously, thereby, possibly leading to additive or else synergistic effects. Theoretically, the combinations of antibodies are very suitable approach that can be employed for the treatment of cancer modalities because of the fact that the antibody combination therapy aids to limit overlapping toxicity along with lack of pharmacokinetic (PK) interactions.

The hypothesis of combining antibodies with other therapeutic agents began in the late 1990s when the researchers together with scientists amplified the preclinical testing that includes a combinations of monoclonal antibodies (mAb) with chemotherapy, radiotherapy or any other therapeutic agents in order to address the occurrence of drug resistant strains or the escape mechanism for observed in cancer malignancies. The main purpose of these investigations was to expand the therapeutic index as well as the potential of mAbs. Advantages such as amended efficiency, diminished toxicities, delayed development of therapy or drug resistances in addition dose reduction were observed in the preclinical studies that come along with antibody combinations.

In dichotomy with the conventional treatments such as chemotherapy and radiotherapy, which clenches the possibility to damage healthy cells, with the arrival of antibody combination therapies has transformed the landscape of targeted medicine. As of now, multiple antibody combination therapies such as Phesgo, Herceptin with Perjeta, Ramucirumab with docetaxel, atezolizumab, Bevacizumab with chemotherapy, atezolizumab and bevacizumab, and ipilimumab and nivolumab etc have been

approved by the FDA, EMA, NICE and others for the treatment of diverse type of cancers.

In the realm of cancer therapy, the preliminary clinical development for the domain of antibody combinations were focused on creating anti-PD-1, anti-CTLA-4 and anti-PD-L1 monoclonal antibody (mAb) combinations, there has been modern improvement observed in harnessing the potential of mAb in conjugation with chemotherapy or with various oral small molecule multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) or platelet derived growth factor receptor (PDGFR) as the first-line treatment for multiple types of cancer like advanced solid tumors, hematological cancer, etc. Zhejiang University based in China is conducting clinical studies in which the combination of anti-PD-1 antibody with Donafenib, multikinase inhibitor, is ongoing to evaluate the safety and efficacy of the treatment regimen.

Another pharmaceutical company based in China, Chia Tai Tianqing Pharmaceutical Group reported another combination of anti-PD-1 antibody, Penpulimab with multi targeted receptor TKI, Anlotinib for the treatment of patients suffering from hepatocellular cancer (HCC). The primary goal of this study is to assess the effectiveness of combined treatment regimen for adjuvant therapy. It is a randomized, double-blind, placebo-controlled, multicenter phase 3 study which was initiated in May 2023 and is expected to be complete by December 2026.

Hitherto, the clinical pipeline for the domain of antibody combination therapy for treating cancer modalities majorly consists of immune checkpoint inhibitors, such as CTLA-4, PD-1 and PD-L1, PP2A inhibitors, CDK4/6 inhibitors, mAbs targeting HER 2, TIGIT mAbs, bispecific antibodies, CAR T cell therapies, antibody drug conjugates, and others. It is expected that the imminent years will certainly witness innovative antibody combinations for the treatment of cancer malignancies as evident from augmenting interest in pharmaceutical sectors and fostering FDA designations to novel combination therapy. For instance, in August 2023, Agenus was granted the Fast Track Designation for its innovative antibody combination, botensilimab (AGEN1181) and balstilimab (AGEN2034) for the treatment of colorectal cancer patients.

With the increasing prevalence of cancer types at an alarming gait urges the need to develop better as well as innovative antibody combination therapies which could provide cure in addition to anticipation amidst the populace suffering from cancer across the globe. Furthermore, an inclining market trend towards utilizing the realm of antibody combination has been observed due to involvement of various stakeholders from pharmaceutical and biotech companies such as Pfizer, Bristol-Myers Squibb,

AstraZeneca, Daiichi Sankyo, Agenus, Novartis, Celldex Therapeutics and Merck. With the current market scenario, the future of the antibody combination market looks promising and is expected to multiple further as evident from the growing clinical trials, rising research and development and involvement of various stakeholders in the domain.

## Contents

### **1. INTRODUCTION TO CANCER ANTIBODY COMBINATIONS**

- 1.1 History, Development & Evolution
- 1.2 Approved Cancer Antibody Combinations

### **2. NEED OF ANTIBODY COMBINATIONS**

### **3. GLOBAL CANCER ANTIBODY COMBINATIONS MARKET & CLINICAL DEVELOPMENT INSIGHT**

- 3.1 Current Market Scenario
- 3.2 Future Outlook

### **4. GLOBAL ANTIBODY COMBINATIONS MARKET INSIGHT BY REGION**

- 4.1 US
- 4.2 China
- 4.3 Europe
- 4.4 Japan
- 4.5 UK
- 4.6 Canada
- 4.7 South Korea

### **5. GLOBAL CANCER ANTIBODY COMBINATIONS CLINICAL TRIALS OVERVIEW**

- 5.1 By Antibody Classification
- 5.2 By Breakthrough Therapy & Fast Track Status
- 5.3 By Company
- 5.4 By Country
- 5.5 By Indication
- 5.6 By Phase

### **6. GLOBAL ANTIBODY COMBINATIONS MARKET INSIGHT BY INDICATION**

- 6.1 Lung Cancer
- 6.2 Melanoma

- 6.3 Breast Cancer
- 6.4 Hepatocellular Cancer
- 6.5 Colorectal Cancer
- 6.6 Renal Cell Carcinoma
- 6.7 Lymphoma
- 6.8 Leukemia
- 6.9 Multiple Myeloma

## **7. GLOBAL CANCER ANTIBODY COMBINATIONS CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE**

- 7.1 Research
- 7.2 Preclinical
- 7.3 Phase-I
- 7.4 Phase-I/II
- 7.5 Phase-II
- 7.6 Phase-II/III
- 7.7 Phase-III
- 7.8 Preregistration
- 7.9 Registered

## **8. APPROVED/MARKETED CANCER ANTIBODY COMBINATIONS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY & INDICATION**

## **9. ANTIBODY - ANTIBODY COMBINATIONS – PRICING, PATENT & DOSING INSIGHT**

- 9.1 Opdivo + Yervoy
    - 9.1.1 Overview & Patent Insight
    - 9.1.2 Pricing & Dosage Insight
  - 9.2 Opdualag (nivolumab & relatlimab)
    - 9.2.1 Overview & Patent Insight
    - 9.2.2 Pricing & Dosage Insight
  - 9.3 Imjudo + Imfinzi
    - 9.3.1 Overview & Patent Insight
    - 9.3.2 Pricing & Dosage Insight
- Detailed Combinations Are Mentioned in Report Sample

## **10. ANTIBODY - SMALL MOLECULE INHIBITORS COMBINATIONS – PRICING, PATENT & DOSING INSIGHT**

### 10.1 Gazyva + Imbruvica

10.1.1 Overview & Patent Insight

10.1.2 Pricing & Dosage Insight

### 10.2 Imbruvica + Rituximab

10.2.1 Overview & Patent Insight

10.2.2 Pricing & Dosage Insight

### 10.3 Bavencio + Inlyta

10.3.1 Overview & Patent Insight

10.3.2 Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample

## **11. ANTIBODY - IMMUNOMODULATORY AGENTS COMBINATIONS – PRICING, PATENT & DOSING INSIGHT**

### 11.1 Monjuvi + lenalidomide

11.1.1 Overview & Patent Insight

11.1.2 Pricing & Dosage Insight

### 11.2 Avastin + Interferon-alfa

11.2.1 Overview & Patent Insight

11.2.2 Pricing & Dosage Insight

## **12. ANTIBODY - CHEMOTHERAPY COMBINATIONS – PRICING, PATENT & DOSING INSIGHT**

### 12.1 Jemperli

12.1.1 Overview & Patent Insight

12.1.2 Pricing & Dosage Insight

### 12.2 Cyramza

12.2.1 Overview & Patent Insight

12.2.2 Pricing & Dosage Insight

### 12.3 Portrazza

12.3.1 Overview & Patent Insight

12.3.2 Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample

## **13. ANTIBODY - MIXED COMBINATIONS**

### 13.1 Phesgo (Perjeta + Herceptin + hyaluronidase)

13.1.1 Overview & Patent Insight

13.1.2 Pricing & Dosage Insight

### 13.2 Darzalex

13.2.1 Overview & Patent Insight

13.2.2 Pricing & Dosage Insight

### 13.3 Empliciti

13.3.1 Overview & Patent Insight

13.3.2 Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample

## **14. COMPETITIVE LANDSCAPE**

14.1 AbbVie

14.2 Adagene

14.3 Agenus

14.4 Akeso Biopharma

14.5 Amgen

14.6 AstraZeneca

14.7 BeiGene

14.8 Biocad

14.9 BioInvent International

14.10 Bio-Thera Solutions

14.11 Boehringer Ingelheim

14.12 Bristol-Myers Squibb

14.13 Concentra Biosciences

14.14 Daiichi Sankyo Company

14.15 Eli Lilly and Company

14.16 Eucure Biopharma

14.17 Genentech

14.18 Genmab

14.19 GSK

14.20 ImmunoGen

14.21 Innovent Biologics

14.22 Janssen Research & Development

14.23 Jiangsu Hengrui Medicine Co.

14.24 LaNova Medicines Limited

14.25 Lepu Biopharma



- 14.26 MacroGenics
- 14.27 Merck
- 14.28 Merus
- 14.29 NGM Biopharmaceuticals
- 14.30 Novartis
- 14.31 Pfizer
- 14.32 Regeneron Pharmaceuticals
- 14.33 Roche
- 14.34 Seagen
- 14.35 Shanghai Henlius Biotech
- 14.36 Shanghai Junshi Biosciences
- 14.37 Sinocelltech
- 14.38 Symphogen
- 14.39 UCB
- 14.40 Xencor

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Developmental Milestones for Antibody Combinations
- Figure 2-1: Comparison of Conventional Therapies v/s Antibody Combination Therapy
- Figure 2-2: Need of Antibody Combinations
- Figure 2-3: Different Combinations of Antibodies with Other Therapeutic Agents
- Figure 2-4: Expected Antibody Combinations
- Figure 3-1: Global – Cancer Antibody Combination Market Opportunity (US\$ Billion),

### 2023 - 2028

- Figure 3-2: Antibody Combination Market - Prominent Regions
- Figure 3-3: Aspects of Current Antibody Combinations Market
- Figure 3-4: Future Characteristics of Antibody Combinations Market
- Figure 4-1: COMBI-i Phase III Study – Initiation & Completion Years
- Figure 4-2: CONTACT-01 Phase III Study – Initiation & Completion Years
- Figure 4-3: NCT05800015 Phase II/III Study – Initiation & Completion Years
- Figure 4-4: MagnetisMM-4 Phase II Study – Initiation & Completion Years
- Figure 4-5: DREAMM 6 Phase I/II Study – Initiation & Completion Years
- Figure 4-6: NCT04421352 Phase I Study – Initiation & Completion Year
- Figure 4-7: NCT05867121 Phase I Study – Initiation & Completion Year
- Figure 4-8: NCT06054477 Phase I/II Study – Initiation & Completion Year
- Figure 4-9: NCT04868877 Phase I/II Study – Initiation & Completion Year
- Figure 4-10: NCT05867121 Phase I Study – Initiation & Completion Year
- Figure 4-11: NCT06038578 Phase II Study – Initiation & Completion Year
- Figure 4-12: DESTINY-Breast01 Phase II Study – Initiation & Completion Year
- Figure 4-13: BI-1607 & Trastuzumab Phase I/II Study – Initiation & Completion Year
- Figure 4-14: Myechild01 Phase III Study – Initiation & Completion Year
- Figure 4-15: GS-9911 & Zimberelimab Phase I Study – Initiation & Completion Year
- Figure 4-16: EGIA-002 Phase II Study – Initiation & Completion Year
- Figure 4-17: TUC1PI-01 Phase I/II Study – Initiation & Completion Year
- Figure 4-18: TUC1PI-01 Phase I/II Study – Initiation & Completion Year
- Figure 4-19: LEAP-008 Phase III Study – Initiation & Completion Year
- Figure 4-20: VOLGA Phase III Study – Initiation & Completion Year
- Figure 4-21: MarkV-01 Phase I Study – Initiation & Completion Year
- Figure 5-1: Global – Cancer Antibody Combinations Clinical Trials By Antibody

Classification, 2023 till 2028

Figure 5-2: Global – Cancer Antibody Combinations Clinical Trials By Priority Status,

## **2023 TILL 2028**

Figure 5-3: Global – Cancer Antibody Combinations Clinical Trials By Company, 2023 till 2028

Figure 5-4: Global – Cancer Antibody Combinations Clinical Trials By Country, 2023 till 2028

Figure 5-5: Global – Cancer Antibody Combinations Clinical Trials By Indication, 2023 till 2028

Figure 5-6: Global – Cancer Antibody Combinations Clinical Trials By Phase, 2023 till

## **2028**

Figure 6-1: Lung Cancer – Approved Antibody Combinations

Figure 6-2: Cemiplimab & Fianlimab Phase II/III Study – Initiation & Completion Year

Figure 6-3: Daratumumab, Nivolumab & KRAS vaccine Phase II Study – Initiation & Completion Year

Figure 6-4: Lung Cancer - Clinical Pipeline of Antibody Combinations

Figure 6-5: Melanoma – Approved Antibody Combinations

Figure 6-6: NCT05608291 Phase III Study – Initiation & Completion Year

Figure 6-7: OrienX010-II-11 Phase I Study – Initiation & Completion Year

Figure 6-8: MM1636 Phase I/II Study – Initiation & Completion Year

Figure 6-9: Breast Cancer - Approved Antibody Combinations

Figure 6-10: Trastuzumab & Pyrotinib Phase III Study – Initiation & Completion Year

Figure 6-11: Inetetamab, Toripalimab & Paclitaxel Phase IV Study – Initiation & Completion Year

Figure 6-12: Breast Cancer – Key Player in Antibody Combination Commercial Market

Figure 6-13: Breast Cancer – Different Antibody Combination With Other Therapeutic Agents

Figure 6-14: Hepatocellular Cancer– Approved Antibody Combinations

Figure 6-15: Combination of Antibody with DEB-TACE to Treat Hepatocellular Carcinoma

Figure 6-16: Penpulimab & Anlotinib Phase III Study – Initiation & Completion Year

Figure 6-17: Collaboration of XNK Therapeutics with Global Pharma Company

Figure 6-18: Antibody Combinations - Benefits to treat Colorectal Cancer

Figure 6-19: NCT06099951 Phase II Study – Initiation & Completion Year

Figure 6-20: KEYFORM-007 Phase III Study – Initiation & Completion Year

- Figure 6-21: Renal Cell Carcinoma – Approved Antibody Combinations
- Figure 6-22: SillaJen & Regeneron Pharmaceuticals – Novel Approach of Combining Oncolytic Vaccinia Virus to Treat Renal Cell Carcinoma
- Figure 6-23: BMC128 & Nivolumab Phase I Study – Initiation & Completion Year
- Figure 6-24: Lymphoma – Approved Antibody Combinations
- Figure 6-25: NCT04464798 Phase I Study – Initiation & Completion Year
- Figure 6-26: Odronextamab, Lenalidomide & Rituximab Phase III Study – Initiation & Completion Year
- Figure 6-27: L-DEP & PD-1 Antibody Phase III Study – Initiation & Completion Year
- Figure 6-28: Collaboration of MorphoSys & Incyte, IGM Bioscience & ADC Therapeutic, 2022
- Figure 6-29: Leukemia – Approved Antibody Combinations
- Figure 6-30: NCT06043674 Phase II Study – Initiation & Completion Year
- Figure 6-31: NP137, Venetoclax & Azacitidine Phase I/II Study – Initiation & Completion Year
- Figure 6-32: Novartis – Hypothesis for Phase 3 Clinical Study
- Figure 6-33: Sabatolimab & Azacitidine Phase III Study – Initiation & Completion Year
- Figure 6-34: Multiple Myeloma – Approved Antibody Combinations
- Figure 6-35: NCT05730036 Phase III Study – Initiation & Completion Year
- Figure 6-36: Pharmaceutical Companies Conducting Phase 3 Studies for Multiple Myeloma
- Figure 6-37: NCT05363111 Phase I Study – Initiation & Completion Year
- Figure 9-1: Opdivo & Yervoy – Minimum Market Exclusivity Year by Region
- Figure 9-2: Opdivo & Yervoy – FDA Approval Years by Indications
- Figure 9-3: Opdivo & Yervoy – EMA Approval Years by Indications
- Figure 9-4: US – Opdivo Cost per Unit & Supply (US\$), December'2023
- Figure 9-5: US – Yervoy Cost per Unit & Supply (US\$), December'2023
- Figure 9-6: EU – Opdivo Cost of Supply (US\$), November'2023
- Figure 9-7: EU – Yervoy Cost of Supply (US\$), November'2023
- Figure 9-8: Opdualag – Approval Years by Region
- Figure 9-9: Opdualag – Minimum Market Exclusivity Year by Region
- Figure 9-10: US & EU – Opdualag Cost per Supply (US\$), November'2023
- Figure 9-11: Imfinzi & Imjudo – Patent Expiry Years by Region
- Figure 9-12: US – Imfinzi Cost per Unit & Supply (US\$), November'2023
- Figure 9-13: US – Imjudo Cost per Unit & Supply (US\$), November'2023
- Figure 9-14: EU – Imfinzi Cost per Unit & Supply (US\$), November'2023
- Figure 9-15: EU – Imjudo Cost per Unit & Supply (US\$), November'2023
- Figure 9-16: US – Keytruda Cost per Unit & Supply (US\$), November'2023

- Figure 9-17: US – Padcev Cost per Unit & Supply (US\$), November'2023  
Figure 9-18: EU – Keytruda Cost per Unit & Supply (US\$), November'2023  
Figure 9-19: EU – Padcev Cost per Unit & Supply (US\$), November'2023  
Figure 9-20: US – Keytruda Cost per Unit & Supply (US\$), November'2023  
Figure 9-21: US – Herceptin Cost per Unit & Supply (US\$), November'2023  
Figure 9-22: US – Trastuzumab Biosimilar Cost per Unit & Supply (US\$),  
November'2023  
Figure 9-23: EU – Keytruda Cost per Unit & Supply (US\$), November'2023  
Figure 9-24: US – Tecentriq Cost per Unit & Supply (US\$), November'2023  
Figure 9-25: US – Avastin Cost per Unit & Supply (US\$), November'2023  
Figure 9-26: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US\$),  
November'2023  
Figure 9-27: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US\$),  
November'2023  
Figure 9-28: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml &

### **160ML (US\$), NOVEMBER'2023**

- Figure 9-29: EU – Tecentriq Cost per Unit & Supply (US\$), November'2023  
Figure 9-30: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US\$),  
November'2023  
Figure 9-31: US – Perjeta Cost per Unit & Supply (US\$), November'2023  
Figure 9-32: US – Herceptin Cost per Unit & Supply (US\$), November'2023  
Figure 9-33: US – Trastuzumab Biosimilar Cost per Unit & Supply (US\$),  
November'2023  
Figure 9-34: EU – Perjeta Cost per Supply (US\$), November'2023  
Figure 9-35: US – Polivy Cost per Supply (US\$), November'2023  
Figure 9-36: US – Rituxan Cost per Unit & Supply (US\$), November'2023  
Figure 9-37: US – Rituximab Biosimilar Cost per Unit & Supply of 10ml (US\$),  
November'2023  
Figure 9-38: US – Rituximab Biosimilar Cost per Unit & Supply of 50ml (US\$),  
November'2023  
Figure 9-39: EU – Polivy Cost per Supply (US\$), November'2023  
Figure 9-40: EU – Rituximab Biosimilar Truxima Cost per Supply (US\$),  
November'2023  
Figure 10-1: US – Imbruvica Cost per Unit & Supply of 70mg (US\$), November'2023  
Figure 10-2: US – Imbruvica Cost per Unit & Supply of 140mg (US\$), November'2023  
Figure 10-3: US – Gazyva Cost per Unit & Supply (US\$), November'2023  
Figure 10-4: US – Imbruvica Cost per Unit & Supply of 70mg (US\$), November'2023

Figure 10-5: US – Imbruvica Cost per Unit & Supply of 140mg (US\$), November'2023

Figure 10-6: US – Rituxan Cost per Unit & Supply (US\$), November'2023

Figure 10-7: US – Rituximab Biosimilar Cost per Unit & Supply of 10ml (US\$),  
November'2023

Figure 10-8: US – Rituximab Biosimilar Cost per Unit & Supply of 50ml (US\$),  
November'2023

Figure 10-9: EU – Rituximab Biosimilar Truxima Cost per Supply (US\$),  
November'2023

Figure 10-10: US – Bavencio Cost per Unit & Supply (US\$), November'2023

Figure 10-11: US – Inlyta Cost per Unit & Supply (US\$), November'2023

Figure 10-12: EU – Bavencio Cost per Unit & Supply (US\$), November'2023

Figure 10-13: EU – Inlyta Cost per Unit & Supply (US\$), November'2023

Figure 10-14: US – Keytruda Cost per Unit & Supply (US\$), November'2023

Figure 10-15: US – Inlyta Cost per Unit & Supply (US\$), November'2023

Figure 10-16: EU – Keytruda Cost per Unit & Supply (US\$), November'2023

Figure 10-17: EU – Inlyta Cost per Unit & Supply (US\$), November'2023

Figure 10-18: US – Cyramza Cost per Unit & Supply (US\$), December'2023

Figure 10-19: US – Tarceva Cost per Supply (US\$), December'2023

Figure 10-20: EU – Cyramza Cost per Unit & Supply (US\$), December'2023

Figure 10-21: US – Keytruda Cost per Unit & Supply (US\$), November'2023

Figure 10-22: US – Lenvima Cost per Unit & Supply (US\$), November'2023

Figure 10-23: EU – Keytruda Cost per Unit & Supply (US\$), December'2023

Figure 10-24: US – Opdivo Cost per Unit & Supply (US\$), November'2023

Figure 10-25: US – Cabometyx Cost per Unit & Supply (US\$), November'2023

Figure 10-26: EU – Opdivo Cost per Unit & Supply (US\$), November'2023

Figure 10-27: EU – Cabometyx Cost per Unit & Supply (US\$), November'2023

Figure 11-1: US – Monjuvi Cost of Supply (US\$), December'2023

Figure 11-2: US – Revlimid Cost per Unit & Supply (US\$), December'2023

Figure 11-3: US – Avastin Cost per Unit & Supply (US\$), December'2023

Figure 11-4: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US\$),  
December'2023

Figure 11-5: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US\$),  
December'2023

Figure 11-6: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml &

### **160ML (US\$), DECEMBER'2023**

Figure 11-7: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US\$),  
December'2023

- Figure 12-1: US & EU – Jemperli Cost of Supply (US\$), December'2023
- Figure 12-2: US – Paclitaxel Cost per Unit & Supply (US\$), December'2023
- Figure 12-3: US – Paraplatin Cost per Unit & Supply (US\$), December'2023
- Figure 12-4: US – Carboplatin Cost per Unit & Supply (US\$), December'2023
- Figure 12-5: US – Cyramza Cost per Unit & Supply (US\$), December'2023
- Figure 12-6: EU – Cyramza Cost per Unit & Supply (US\$), December'2023
- Figure 12-7: US – Taxotere Cost per Unit & Supply (US\$), December'2023
- Figure 12-8: US – Paclitaxel Cost per Unit & Supply (US\$), December'2023
- Figure 12-9: US & EU – Cyramza Cost per Unit & Supply (US\$), December'2023
- Figure 12-10: US – Gemzar Cost of Supply (US\$), December'2023
- Figure 12-11: US – Infugem Cost per Unit & Supply (US\$), December'2023
- Figure 12-12: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US\$), December'2023
- Figure 12-13: US – Vectibix Cost per Unit & Supply (US\$), December'2023
- Figure 12-14: US – Eloxatin Cost per Unit & Supply (US\$), December'2023
- Figure 12-15: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US\$), December'2023
- Figure 12-16: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023
- Figure 12-17: US – Adrucil Cost per Unit & Supply (US\$), December'2023
- Figure 12-18: US – Fluorouracil Cost per Unit & Supply (US\$), December'2023
- Figure 12-19: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US\$), December'2023
- Figure 12-20: US – Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US\$), December'2023
- Figure 12-21: US – Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US\$), December'2023
- Figure 12-22: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US\$), December'2023
- Figure 12-23: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US\$), December'2023
- Figure 12-24: US – Adriamycin Cost of Supply of Intravenous Powder (US\$), December'2023
- Figure 12-25: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023
- Figure 12-26: US – Doxorubicin Cost of Supply of Intravenous Powder (US\$), December'2023
- Figure 12-27: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-28: US – Vincristine Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-29: US – Toposar Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-30: US – Etoposide Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-31: US – Etoposide Cost per Unit & Supply of Oral Capsule (US\$), December'2023

Figure 12-32: US – Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US\$), December'2023

Figure 12-33: US – Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US\$), December'2023

Figure 12-34: US – Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US\$), December'2023

Figure 12-35: US – Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US\$), December'2023

Figure 12-36: US – Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US\$), December'2023

Figure 12-37: US – Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US\$), December'2023

Figure 12-38: US – Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US\$), December'2023

Figure 12-39: US – Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US\$), December'2023

Figure 12-40: US – Vinblastine Cost per Unit & Supply (US\$), December'2023

Figure 12-41: US – Dacarbazine Cost per Unit & Supply for 100mg Intravenous Powder (US\$), December'2023

Figure 12-42: US – Dacarbazine Cost per Unit & Supply for 200mg Intravenous Powder (US\$), December'2023

Figure 12-43: US – Erbitux Cost per Unit & Supply (US\$), December'2023

Figure 12-44: US – Camptosar Cost per Unit & Supply (US\$), December'2023

Figure 12-45: US – Irinotecan Cost per Unit & Supply (US\$), December'2023

Figure 12-46: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US\$), December'2023

Figure 12-47: US – Paraplatin Cost per Unit & Supply (US\$), December'2023

Figure 12-48: US – Carboplatin Cost per Unit & Supply (US\$), December'2023

Figure 12-49: US – Adrucil Cost per Unit & Supply (US\$), December'2023

Figure 12-50: US – Fluorouracil Cost per Unit & Supply (US\$), December'2023

Figure 12-51: US – Leucovorin Cost of Supply of 100mg, 200mg, 350mg & 500mg



Injectable Powder (US\$), December'2023

Figure 12-52: US – Leucovorin Cost per Unit & Supply of Injectable Solution (US\$), December'2023

Figure 12-53: US - Leucovorin Cost per Unit & Supply of 5mg Oral Tablet (US\$), December'2023

Figure 12-54: US - Leucovorin Cost per Unit & Supply of 10mg Oral Tablet (US\$), December'2023

Figure 12-55: US - Leucovorin Cost per Unit & Supply of 15mg Oral Tablet (US\$), December'2023

Figure 12-56: US - Leucovorin Cost per Unit & Supply of 25mg Oral Tablet (US\$), December'2023

Figure 12-57: US – Avastin Cost per Unit & Supply (US\$), December'2023

Figure 12-58: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US\$), December'2023

Figure 12-59: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US\$), December'2023

Figure 12-60: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US\$), December'2023

Figure 12-61: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US\$), December'2023

Figure 12-62: US – Paclitaxel Cost per Unit & Supply (US\$), December'2023

Figure 12-63: US – Paraplatin Cost per Unit & Supply (US\$), December'2023

Figure 12-64: US – Carboplatin Cost per Unit & Supply (US\$), December'2023

Figure 12-65: US – Tecentriq Cost per Unit & Supply (US\$), November'2023

Figure 12-66: US – Gemzar Cost of Supply (US\$), December'2023

Figure 12-67: US – Infugem Cost per Unit & Supply (US\$), December'2023

Figure 12-68: US – Hycamtin Cost of Supply of Oral Capsule (US\$), December'2023

Figure 12-69: US – Topotecan Cost of Supply of Intravenous Solution (US\$), December'2023

Figure 12-70: US – Keytruda Cost per Unit & Supply (US\$), November'2023

Figure 12-71: EU – Keytruda Cost of Supply (US\$), November'2023

Figure 12-72: US – Xeloda Cost per Unit & Supply (US\$), November'2023

Figure 12-73: US – Capecitabine Cost per Unit & Supply of 150mg (US\$), November'2023

Figure 12-74: US – Capecitabine Cost per Unit & Supply of 500mg (US\$), November'2023

Figure 12-75: US – Adrucil Cost per Unit & Supply (US\$), December'2023

Figure 12-76: US – Fluorouracil Cost per Unit & Supply (US\$), December'2023

Figure 12-77: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US\$),

December'2023

Figure 12-78: US – Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US\$), December'2023

Figure 12-79: US – Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US\$), December'2023

Figure 12-80: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US\$), December'2023

Figure 12-81: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US\$), December'2023

Figure 12-82: US – Adriamycin Cost of Supply of Intravenous Powder (US\$), December'2023

Figure 12-83: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-84: US – Doxorubicin Cost of Supply of Intravenous Powder (US\$), December'2023

Figure 12-85: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-86: US – Paclitaxel Cost per Unit & Supply (US\$), December'2023

Figure 12-87: US – Abraxane Cost per Unit & Supply (US\$), December'2023

Figure 12-88: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US\$), December'2023

Figure 12-89: US – Paraplatin Cost per Unit & Supply (US\$), December'2023

Figure 12-90: US – Carboplatin Cost per Unit & Supply (US\$), December'2023

Figure 12-91: US – Eloxatin Cost per Unit & Supply (US\$), December'2023

Figure 12-92: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US\$), December'2023

Figure 12-93: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-94: US – Gemzar Cost of Supply (US\$), December'2023

Figure 12-95: US – Infugem Cost per Unit & Supply (US\$), December'2023

Figure 12-96: US – Gemcitabine Cost of Supply of Intravenous Powder for Injection (US\$), December'2023

Figure 12-97: US – Gemcitabine Cost per Unit & Supply of 38mg/ml Intravenous Solution (US\$), December'2023

Figure 12-98: US – Gemcitabine Cost per Unit & Supply of 100mg/ml Intravenous Solution (US\$), December'2023

Figure 12-99: US – Alimta Cost of Supply (US\$), December'2023

Figure 12-100: US – Pemfexy Cost per Unit & Supply (US\$), December'2023

Figure 12-101: US – Pemetrexed Cost per Unit & Supply of Intravenous Powder for

Injection (US\$), December'2023

Figure 12-102: US – Pemetrexed Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-103: US – Ellence Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-104: US – Epirubicin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-105: US – Herceptin Cost per Unit & Supply (US\$), November'2023

Figure 12-106: US – Trastuzumab Biosimilar Cost per Unit & Supply (US\$), November'2023

Figure 12-107: US – Xeloda Cost per Unit & Supply (US\$), November'2023

Figure 12-108: US – Capecitabine Cost per Unit & Supply of 150mg (US\$), November'2023

Figure 12-109: US – Capecitabine Cost per Unit & Supply of 500mg (US\$), November'2023

Figure 12-110: US – Adrucil Cost per Unit & Supply (US\$), December'2023

Figure 12-111: US – Fluorouracil Cost per Unit & Supply (US\$), December'2023

Figure 12-112: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US\$), December'2023

Figure 12-113: US – Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml & 500mg/ml (US\$), December'2023

Figure 12-114: US – Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US\$), December'2023

Figure 12-115: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US\$), December'2023

Figure 12-116: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US\$), December'2023

Figure 12-117: US – Adriamycin Cost of Supply of Intravenous Powder (US\$), December'2023

Figure 12-118: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-119: US – Doxorubicin Cost of Supply of Intravenous Powder (US\$), December'2023

Figure 12-120: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023

Figure 12-121: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US\$), December'2023

Figure 12-122: US – Paclitaxel Cost per Unit & Supply (US\$), December'2023

Figure 12-123: US – Libtayo Cost per Unit & Supply (US\$), December'2023

- Figure 12-124: US – Libtayo Cost per Unit & Supply (US\$), December'2023
- Figure 12-125: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US\$), December'2023
- Figure 12-126: US – Paraplatin Cost per Unit & Supply (US\$), December'2023
- Figure 12-127: US – Carboplatin Cost per Unit & Supply (US\$), December'2023
- Figure 12-128: US – Eloxatin Cost per Unit & Supply (US\$), December'2023
- Figure 12-129: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US\$), December'2023
- Figure 12-130: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US\$), December'2023
- Figure 13-1: US – Phesgo Cost per Unit & Supply (US\$), December'2023
- Figure 13-2: EU – Phesgo Cost per Unit & Supply (US\$), December'2023
- Figure 13-3: US - Darzalex Cost per Unit & Supply (US\$), November'2023
- Figure 13-4: EU - Darzalex Cost per Unit & Supply (US\$), December'2023
- Figure 13-5: US – Kyprolis Cost per Unit & Supply (US\$), November'2023
- Figure 13-6: US – Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable Solution (US\$), December'2023
- Figure 13-7: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable Solution (US\$), December'2023
- Figure 13-8: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US\$), December'2023
- Figure 13-9: US – Dexamethasone Cost per Unit & Supply of Oral Liquid (US\$), December'2023
- Figure 13-10: US – Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg, 1mg & 6mg Oral Tablets (US\$), December'2023
- Figure 13-11: US – Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets (US\$), December'2023
- Figure 13-12: US – Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets (US\$), December'2023
- Figure 13-13: US – Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets (US\$), December'2023
- Figure 13-14: US – Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets (US\$), December'2023
- Figure 13-15: US – TaperDex Cost per Unit & Supply (US\$), December'2023
- Figure 13-16: US – Velcade Cost per Supply (US\$), November'2023
- Figure 13-17: US – Bortezomib Cost of Supply (US\$), December'2023
- Figure 13-18: US – Thalomid Cost per Unit & Supply of 50mg Capsule (US\$), December'2023
- Figure 13-19: US – Thalomid Cost per Unit & Supply of 100mg & 150mg Capsules

(US\$), December'2023

Figure 13-20: US – Revlimid Cost per Unit & Supply (US\$), December'2023

Figure 13-21: US – Pomalyst Cost per Unit & Supply (US\$), December'2023

Figure 13-22: US – Evomela & Generic Melphalan Cost of Supply (US\$),  
December'2023

Figure 13-23: US – Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US\$),  
December'2023

Figure 13-24: US – Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US\$),  
December'2023

Figure 13-25: US – Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US\$),  
December'2023

Figure 13-26: US – Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US\$),  
December'2023

Figure 13-27: US – Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US\$),  
December'2023

Figure 13-28: US – Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US\$),  
December'2023

Figure 13-29: US – Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US\$),  
December'2023

Figure 13-30: US – Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US\$),  
December'2023

Figure 13-31: US - Empliciti Cost of Supply (US\$), November'2023

Figure 13-32: US – Pomalyst Cost per Unit & Supply (US\$), December'2023

Figure 13-33: US – Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable  
Solution (US\$), December'2023

Figure 13-34: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable  
Solution (US\$), December'2023

Figure 13-35: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-  
Free Injectable Solution (US\$), December'2023

Figure 13-36: US – Dexamethasone Cost per Unit & Supply of Oral Liquid (US\$),  
December'2023

Figure 13-37: US – Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg,

### **1MG, & 6MG ORAL TABLETS (US\$), DECEMBER'2023**

Figure 13-38: US – Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets  
(US\$), December'2023

Figure 13-39: US – Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets  
(US\$), December'2023

Figure 13-40: US – Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets (US\$), December'2023

Figure 13-41: US – Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets (US\$), December'2023

Figure 13-42: US – TaperDex Cost per Unit & Supply (US\$), December'2023

Figure 13-43: US – Keytruda Cost per Unit & Supply (US\$), December'2023

Figure 13-44: EU – Keytruda Cost of Supply (US\$), December'2023

Figure 13-45: US – Herceptin Cost per Unit & Supply (US\$), November'2023

Figure 13-46: US – Trastuzumab Biosimilar Cost per Unit & Supply (US\$), November'2023

Figure 13-47: US – Avastin Cost per Unit & Supply (US\$), December'2023

Figure 13-48: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US\$), December'2023

Figure 13-49: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US\$), December'2023

Figure 13-50: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US\$), December'2023

Figure 13-51: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US\$), December'2023

Figure 13-52: US – Paclitaxel Cost per Unit & Supply (US\$), December'2023

Figure 13-53: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US\$), December'2023

Figure 13-54: US – Paraplatin Cost per Unit & Supply (US\$), December'2023

Figure 13-55: US – Carboplatin Cost per Unit & Supply (US\$), December'2023

Figure 13-56: US – Xeloda Cost per Unit & Supply (US\$), November'2023

Figure 13-57: US – Capecitabine Cost per Unit & Supply of 150mg (US\$), November'2023

Figure 13-58: US – Capecitabine Cost per Unit & Supply of 500mg (US\$), November'2023

Figure 13-59: US – Adrucil Cost per Unit & Supply (US\$), December'2023

Figure 13-60: US – Fluorouracil Cost per Unit & Supply (US\$), December'2023

Figure 13-61: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US\$), December'2023

Figure 13-62: US – Paraplatin Cost per Unit & Supply (US\$), December'2023

Figure 13-63: US – Carboplatin Cost per Unit & Supply (US\$), December'2023

Figure 13-64: US – Eloxatin Cost per Unit & Supply (US\$), December'2023

Figure 13-65: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US\$), December'2023

Figure 13-66: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US\$),

December'2023

Figure 13-67: US – Sarclisa Cost per Unit & Supply (US\$), December'2023

Figure 13-68: US – Kyprolis Cost per Unit & Supply (US\$), December'2023

Figure 13-69: EU – Sarclisa Cost per Unit & Supply (US\$), December'2023

Figure 13-70: US – Pomalyst Cost per Unit & Supply (US\$), December'2023

## List Of Tables

### LIST OF TABLES

Table 1-1: Global – Approved Cancer Antibody Combinations

Table 9-1: Opdivo & Yervoy Combination – Recommended Dosages

Table 9-2: Imjudo & Imfinzi - Recommended Dosage Schedule for Treatment of NSCLC

Table 10-1: Dose of Gazyva to be Administered During Six 28-Day Treatment Cycles for Patients with CLL

Table 10-2: Cabometyx & Nivolumab - Recommended Dosage of Combination

Table 11-1: Monjuvi - Dosing Schedule

Table 12-1: Jemperli - Recommended Dosage

Table 12-2: US – Approved Cyramza-Chemotherapy Combinations

Table 12-3: US – Approved Vectibix-Chemotherapy Combinations

Table 12-4: US – Approved Adcetris-Chemotherapy Combinations

Table 12-5: Adcetris - Recommended Dosage

Table 12-6: US – Approved Erbitux-Chemotherapy Combinations

Table 12-7: US – Approved Avastin-Chemotherapy Combinations

Table 12-8: US – Approved Keytruda-Chemotherapy Combinations

Table 12-9: Keytruda - Recommended Doses

Table 12-10: US – Approved Herceptin-Chemotherapy Combinations

Table 13-1: Phesgo: Recommended Dosage & Administration Schedule

Table 13-2: US – Approved Darzalex-Chemotherapy Combinations

Table 13-3: Darzalex - Dosing Schedule in Combination with Lenalidomide or Pomalidomide (4-Week Cycle) & Low-Dose Dexamethasone

Table 13-4: Darzalex - Dosing Schedule in Combination with Bortezomib, & Prednisone ([VMP], 6-Week Cycle)

Table 13-5: Darzalex - Dosing Schedule in Combination with Bortezomib, Thalidomide & Dexamethasone ([VTd]; 4-Week Cycle)

Table 13-6: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week Cycle)

Table 13-7: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week Cycle)

Table 13-8: Empliciti - Recommended Dosing Schedule in Combination with Lenalidomide & Dexamethasone

Table 13-9: Empliciti - Recommended Dosing Schedule in Combination with Pomalidomide & Dexamethasone

Table 13-10: US – Approved Keytruda-Chemotherapy Combinations



Table 13-11: Keytruda - Recommended Dosage

Table 13-12: US – Approved Sarclisa-Chemotherapy Combinations

Table 13-13: Sarclisa - Dosing Schedule in Combination with Pomalidomide & Dexamethasone or in Combination with Carfilzomib & Dexamethasone

## I would like to order

Product name: Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/GA0CC3DFF48AEN.html>

Price: US\$ 6,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA0CC3DFF48AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970